ClinicalTrials.gg
CompletedNCT01111279Updated Mar 1, 2011

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

A Phase 1 interventional study of gpASIT+TM and gpAST+TM/adjuvant in Seasonal Allergic Rhinoconjunctivitis, sponsored by BioTech Tools S.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2011-03-01.

Sponsored by BioTech Tools S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.

02

Conditions studied

  • Seasonal Allergic Rhinoconjunctivitis
03

In context

Lead sponsor

BioTech Tools S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has given written
  • Age between 18 and 50 years
  • The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status
  • Male or non pregnant, non-lactating female
  • Females unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or post menopausal (defined as a minimum of one year since the last menstrual period))
  • Allergy diagnosis:

    • A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least during the two previous years
    • A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture
    • Specific IgE against grass pollen (RAST class 2 or IgE > 0.7 kU/l)
    • Asymptomatic to perennial inhalant allergens even if shown to be hypersensitive in a skin prick test.

Exclusion criteria

Exclusion Criteria:

  • Subjects with current or past immunotherapy (any time in the past)
  • A history of to the
  • Subjects requiring control medication against asthma (bronchodilator nebulised drugs or local or systemic )
  • Subjects with documented evidence of acute or significant chronic sinusitis (as determined by investigator)
  • Subjects with a history of hepatic or renal disease
  • Subjects symptomatic to perennial inhalant allergens
  • Subjects with rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative agent...)
  • Subject with malignant disease, disease (and family medical history of autoimmune disease)
  • Any chronic disease, which may impair the subject's ability to participate in the trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer, uncontrolled diabetes mellitus, etc...)
  • Subjects requiring beta-blockers medication
  • Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants)
  • Subject with febrile illness (> 37.5°C, oral)
  • A known positive serology for -1/2, HBs antigen or anti- antibodies
  • The subject is by medication or illness, has received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry
  • Receipt of blood or a blood derivative in the past 6 months preceding trial entry
  • Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 4 weeks preceding the trial
  • Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 1 week preceding the trial
  • Use of long-acting antihistamines
  • Female subjects who are pregnant, lactating, or of and not protected from pregnancy by a sufficiently reliable method (OCs, IUD)
  • Any condition which could be incompatible with protocol understanding and compliance
  • Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship
  • Unreliable subjects including non-compliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give or to abide by the requirements of the protocol
  • Subjects without means of contacting the investigator rapidly in case of emergency, or not able to be contacted rapidly by the investigator
  • Participation in another clinical trial and/or treatment with an experimental drug within 1 month of trial start
  • Subjects who participated to trial BTT-gpASIT003 and were in the treated groups
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Biological: Placebo solution

  • Experimental
    gpASIT+TM

    Biological: gpASIT+TM

  • Experimental
    gpASIT+TM/adjuvant

    Biological: gpAST+TM/adjuvant

Interventions

  • BiologicalgpASIT+TM

    Drug page: gpASIT+

    1 subcutaneous injection every 7 days, during 29 days.

  • BiologicalgpAST+TM/adjuvant

    Drug page: Adjuvant

    1 subcutaneous injection every 7 days, during 29 days

  • BiologicalPlacebo solution

    1 subcutaneous injection every 7 days, during 29 days

06

What researchers measure

Primary outcomes

  1. Clinical tolerability and safety of the treatment

    The following parameters will be assessed : general physical status, vital signs, haematological parameters , general blood biochemistry parameters, all (serious) adverse, immunological analysis (total IgG, total IgE) and inflammatory parameters (CRP, sedimentation rate)

    Time frame: 3 times during the treatment phase, at week 24 (the end of the study)

Secondary outcomes

  1. Impact of gpASIT+TM on the immunological status of the subjects

    The following parameters will be assessed : * allergen-specific IgE, IgG, IgG4, IgA antibody concentrations, * adjuvant-specific IgG antibody concentrations, * lymphoproliferation and production of IL-10 in allergen and adjuvant stimulated PBMC.

    Time frame: visit 1, week 7, week 18 and week 24

  2. Impact of gpASIT+TM on the clinical status of the subjects

    The following parameters will be assessed (during the pollen season following treatment): * daily average allergic symptom score, * daily average allergic medication score, * number of "well-days", * Visual Analogue Scale .

    Time frame: 1 May - 15 August 2010

07

Study locations

1 site
  • UZ Leuven, Gasthuisberg
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Sep 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2010
First posted
Apr 27, 2010
Start
Mar 2010
Primary completionActual
Sep 2010
CompletionActual
Nov 2010
Last update
Mar 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01111279
Lead sponsor
BioTech Tools S.A.
First posted
Apr 27, 2010
Start date
Mar 2010
Primary completion
Sep 2010
Completion
Nov 2010
Last update
Mar 1, 2011

Study contacts

Jan Ceuppens, Professor
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: gpASIT+ · Adjuvant

Start the discussion